Thrivent Financial for Lutherans
RCKT icon

Thrivent Financial for Lutherans’s Rocket Pharmaceuticals RCKT Stock Holding History

Thrivent Financial for Lutherans’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35,817
Closed -$117K – 2633
2025
Q3 		$117K Sell
35,817
-17,629
-33% -$55.5K ﹤0.01% 2346
2025
Q2 		$131K Hold
53,446
– – ﹤0.01% 2412
2025
Q1 		$356K Hold
53,446
– – ﹤0.01% 2184
2024
Q4 		$671K Sell
53,446
-21,731
-29% -$327K ﹤0.01% 2129
2024
Q3 		$1.39M Hold
75,177
– – ﹤0.01% 1698
2024
Q2 		$1.62M Sell
75,177
-3,210
-4% -$73.7K ﹤0.01% 1532
2024
Q1 		$2.11M Hold
78,387
– – ﹤0.01% 1370
2023
Q4 		$2.35M Sell
78,387
-3,827
-5% -$84.5K 0.01% 1279
2023
Q3 		$1.68M Buy
+82,214
New +$1.49M ﹤0.01% 1410

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Thrivent Financial for Lutherans's RCKT Position: Q4 2025 in Review

Thrivent Financial for Lutherans sold out of Rocket Pharmaceuticals (RCKT) in Q4 2025, closing a stake of 35,817 shares — an estimated $117K sold.

Thrivent Financial for Lutherans first reported a position in RCKT in Q3 2023 and held it in 9 quarters. The position peaked at $2.35M in Q4 2023. 186 funds tracked by Wall St. Rank hold RCKT as of Q4 2025.

  • Thrivent Financial for Lutherans reported no remaining Rocket Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 35,817 Rocket Pharmaceuticals shares in Q4 2025, an estimated $117K.
  • Thrivent Financial for Lutherans first reported a position in Rocket Pharmaceuticals in Q3 2023 and held it in 9 quarters.
  • Thrivent Financial for Lutherans's Rocket Pharmaceuticals position peaked at $2.35M in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2025, filed 5 Feb 2026.